Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus LEXETTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus LEXETTE.
ARAZLO vs LEXETTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
LEXETTE (halobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects. The primary mechanism involves binding to glucocorticoid receptors, which modulates gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply to affected areas once daily for up to 2 weeks. Use no more than 60 g per week.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life is 12-15 hours, supporting twice-daily dosing in clinical practice.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily renal excretion of unchanged drug (approximately 70%), with 30% metabolized hepatically via CYP3A4 and excreted as inactive metabolites in urine and feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid